Despite the renoprotective role, the synthetic PPAR-γ agonists such as rosiglitazone, pioglitazone, and troglitazone are also reported to show various adverse effects such as fluid retention or blood volume expansion, obesity, heart disease and hepatotoxicity (Sauer, 2015). This evidence concerns the gene PPARG and obesity due to melanocortin 4 receptor deficiency.